Analysis of biological and genetic stability of tick-borne encephalitis strain 205 used in the production of tick-borne encephalitis vaccines EnceVir and EnceVir Neo for children

The article presents the results of a long-term study of biological and genetic stability of tick-borne encephalitis strain 205 which is used by the FSUE «SPA «Microgen» to produce tick-borne encephalitis vaccines EnceVir (for adults) and EnceVir Neo for children, both of which are tissue cultured, inactivated, purified, and sorbed. The biological stability of strain 205 was studied at the seed lot stage using passages on outbred white mice: initial production strain 205 and production «stock strain». Lyophilisates of production seed lots were studied at different storage intervals at -20 °С (up to 9 years of storage and more). Biological activity parameters (tick-borne encephalitis virus (TBEV) titre in log LD₅₀/ml) were studied by using different ways of infecting outbred white mice, and strain 205 identification (specificity) was determined by comparing it to a reference strain in a biological neutralization assay (BNA) according to the manufacturer’s specifications for the vaccines concerned. The same materials and a batch of TBEV vaccine produced from the production «stock strain» (lyophilisate of 1986) were analyzed by polymerase chain reaction (PCR) and sequencing for genetic stability during passaging and long-term storage. The results of the study made it possible to demonstrate the biological and genetic stability of strain 205 during production of TBEV vaccines.

клещевой энцефалит, вакцинация, производство вакцин клещевого энцефалита, биологическая и генетическая стабильность, подлинность в реакции биологической нейтрализации, пассажи через мозг аутбредных белых мышей, полимеразная цепная реакция, праймеры, секвенирование, tick-borne encephalitis, vaccination, production of tick-borne encephalitis vaccines, biological and genetic stability, identification in a biological neutralization assay, outbred white mouse brain passage, polymerase chain reaction, primers, sequencing

1. Vorobieva MS, Merkulov VA, Ladyzhenskaya IP, Rukavishnikov AV, Shevtsov VA. The history and quality evaluation of tick-borne encephalitis vaccine. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2013; (3): 40–4 (in Russian).

2. Barrett PN, Plotkin SA, Ehrlich HJ. Tick-borne encephalitis virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier; 2008. P. 841–56.

3. Morozova OV. Problems and prospects of prevention, diagnosis and treatment of tick-borne encephalitis. Rossiyskiy meditsinskiy zhurnal 2014; 20(6): 26–31 (in Russian).

4. Pastorino BA, Peyrefitte CN, Grandadam M, Thill MC, Tolou HJ, Bessaud M. Mutagenesis analysis of the NS2B determinants of the Alkhurma virus NS2B-NS3 protease activation. J Gen Virol. 2006; 87: 3279–83.

5. Pöllabauer EM, Pavlova BG, Löw-Baselli A, Fritsch S, Prymula R, Angermayr R, et al. Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine 2010; 28(29): 4680–5.

6. Gorbunov MA, Pavlova LI, Vorobieva MS, Raschepkina MN, Stronin OB. Results of clinical trials of a vaccine against tick-borne encephalitis EnceVir. Epidemiologiya i vaktsinoprofilaktika 2002; (1): 64–8 (in Russian).

7. Romanenko VV, Ankudinova AV, Kilyachina AS. The effectiveness of the program of mass vaccination encephalitis in the Sverdlovsk Region. Vestnik UGMA 2010; (21): 125–32 (in Russian).

8. Vorobieva MS Raschepkina MN, Krasilnikov IV, Mischenko IA, Sharov OI, Ryumin TA Bilalova GP. The results of laboratory tests of the modified vaccine «EnñeVir» against tick-borne encephalitis, produced by FSUE «VIRION». In: Topical issues of development, production and use of immunobiological and pharmaceutical preparations. Abstracts of Conference, 2001. P. 8–11 (in Russian).

9. Kotykov IV, Kiseleva NN, Fedorov YuV. Study of the population of production strain 205 of the virus of tick-borne encephalitis. In: Abstracts of the All-Union Symposium «Modern epidemiology problems, diagnosis and prevention of tick-borne encephalitis», 1990. P. 71–2 (in Russian).

10. Holzmann H, Vorobyova ÌS, Ladyzhenskaya IP, Forenczi E, Kundi M, Kunz C, Heinz FX. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine 1992; 10(5): 345–9.

11. ICH Guidance, Q5D: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products (63 FR 50244; September 21, 1998).

12. Andreev YuL, Maeva TV, Kedich LA, Zolina ED, Kusliy AG. Physico-chemical and immunological characteristics of the vaccine «Hep-in-a-vak» at different storage conditions. Biopreparation. Prevention, Diagnosis, Treatment 2008; (4): 26–8 (in Russian).

13. Ecker M, Allison SL, Meixner T, Heinz FX. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol. 1999; 80(1): 179–85.

14. ICH Guidance, Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (63 FR 51074; September 24, 1998).

15. Akey DL, Brown WC, Dutta S, Konwerski J, Jose J, Jurkiw TJ, et al. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science 2014; 343(6173): 881–5.

16. Leung JY, Pijlman GP, Kondratieva N, Hyde J, Mackenzie JM, Khromykh AA. Role of nonstructural protein NS2A in flavivirus assembly. J Virol. 2008; 82(10): 4731–41.

17. Kofler RM, Heinz FX, Mandl CW. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence. J Virol. 2002; 76(7): 3534–43.

18. Mandl CW, Heinz FX, Stockl E, Kunz C. Genome sequence of tick-borne encephalitis virus (Western subtype) and comparative analysis of nonstructural proteins with other flaviviruses. Virology 1989; 173(1): 291–301.

19. Zent O, Bröker M. Tick-borne encephalitis vaccines: past and present. Expert Rev Vaccines. 2005; 4(5): 747–55.